Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...

New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocyt ...

In a significant move within the biopharmaceutical sector, Sanofi has once again turned to Dren Bio, committing an impressive $100 million upfront for further development of B cell depletion therapies ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi to develop therapies ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Amid positive trial results, ZYNLONTA has already received accelerated approval from the FDA and conditional approval from ...